SUNNYVALE, Calif., May 13, 2026
Cepheid, a Danaher company, announced that it has received CE marking under the European Union’s In Vitro Diagnostic Regulation (IVDR) for its Xpert® GI Panel, a multiplex PCR diagnostic test capable of detecting 11 clinically relevant gastrointestinal pathogens from a single patient sample. The latest regulatory milestone strengthens Cepheid’s expanding molecular diagnostics portfolio and highlights growing industry demand for rapid syndromic testing solutions in infectious disease management.
The newly approved assay is designed to run on Cepheid’s widely used GeneXpert® systems equipped with advanced 10-color multiplexing technology, enabling laboratories and healthcare providers to rapidly identify bacterial, viral, and parasitic gastrointestinal infections with minimal hands-on time. According to the company, the workflow requires less than one minute of manual preparation, while delivering results in approximately 74 minutes.
The approval comes at a time when healthcare systems globally are increasing investments in rapid molecular diagnostics to improve patient outcomes, reduce healthcare-associated infections, and strengthen outbreak management capabilities. Gastrointestinal infections remain a significant public health burden worldwide, particularly among pediatric and immunocompromised populations.
Multiplex PCR Technology Enhances Diagnostic Speed
Cepheid stated that the Xpert GI Panel simultaneously detects 11 clinically important pathogens directly from stool samples collected in Cary-Blair transport media. The multiplex PCR system is designed to simplify laboratory workflows while improving diagnostic efficiency compared with traditional stool culture methods that often require extensive manual processing and can take several days to generate results.
Advertisement
Traditional gastrointestinal diagnostic testing can be challenging because many infections present with overlapping symptoms such as diarrhea, abdominal pain, fever, and vomiting. Conventional culture-based methods may also fail to identify co-infections or low-abundance pathogens. In contrast, multiplex molecular testing allows clinicians to evaluate multiple infectious agents simultaneously, enabling faster clinical decision-making and potentially reducing inappropriate antimicrobial use.
Clinical experts highlighted the operational advantages of the system for routine microbiology laboratories. Researchers noted that diagnostic platforms combining broad pathogen coverage with streamlined workflows are increasingly important for hospitals and public health laboratories managing growing testing volumes and evolving infectious disease threats.
IVDR Compliance Strengthens European Market Position
The CE marking under IVDR represents an important commercial and regulatory achievement for Cepheid because the European Union’s updated diagnostic regulations impose stricter requirements for clinical evidence, quality systems, and post-market surveillance compared with previous frameworks. The approval demonstrates that the Xpert GI Panel meets enhanced European standards for diagnostic safety, analytical performance, and clinical utility.
Cepheid emphasized that the GI panel complements the company’s existing infectious disease testing menu, which already includes standalone molecular assays for pathogens such as Clostridioides difficile and Norovirus. The company said clinicians can now expand from targeted single-pathogen testing to comprehensive syndromic gastrointestinal testing using the same GeneXpert workflow already deployed in hospitals and laboratories worldwide.
The latest launch also reflects the broader healthcare industry trend toward decentralized and rapid molecular diagnostics capable of supporting clinical decisions closer to the patient. Cepheid’s GeneXpert systems are already widely used across respiratory disease testing, tuberculosis diagnostics, oncology, virology, and antimicrobial resistance screening.
Expanding Global Access to Molecular Diagnostics
Cepheid confirmed that shipments of the Xpert GI Panel to countries recognizing the CE mark will begin in the coming weeks, potentially expanding access to advanced gastrointestinal pathogen testing across hospitals, diagnostic laboratories, and healthcare systems internationally.
The IVDR approval further strengthens Cepheid’s position in the global molecular diagnostics market, where demand for high-throughput, automated PCR testing platforms continues to rise due to increasing awareness of infectious disease surveillance, antimicrobial stewardship, and precision diagnostics.
Source: Cepheid press release
